

**Date: February 09, 2024**

To,  
The Deputy Gen. Manager,  
Metropolitan Stock Exchange of India Ltd  
Vibgyor Towers, 4<sup>th</sup> Floor, Plot No. C-62,  
G-Block, Opp. Trident, Bandra-Kurla Complex,  
Bandra (E), Mumbai-400 098

Dear Sir / Madam,

**Sub: Outcome of Board Meeting of Jagadishwar Pharmaceutical Works Limited held on February 09, 2024**

**Ref: Regulation 33 (3) of SEBI (Listing Obligation and Disclosures Requirements) Regulations 2015**

With reference to the above captioned subject, outcome of the meeting of the Board of Directors of Jagadishwar Pharmaceutical Works Limited which was held today at 04.30 p.m. and concluded at 05.00 p.m. is as follows:

Approved Unaudited Financial Results of the Company for the quarter ended December 31, 2023 were considered and approved by the Board.

Find enclosed herewith a copy of Unaudited Financial Results along with Limited Review Report pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

You are requested to take note of the same.

Thanking You,  
**For Jagadishwar Pharmaceutical Works Limited**

Digitally signed by  
GUNODHAR  
GHOSH  
AR GHOSH Date: 2024.02.09  
17:08:07 +05'30'

**Gunodhar Ghosh**  
**Executive Director**  
**DIN : 08524622**

**Encl: As above**

# Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

**Regd Office:** 205, Haribol Roy Market, A.T.Road, 2nd Floor, Near Saraf Building, Guwahati - 781 001

**Corp. Office :** 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

**Email:** jpw ltd@yahoo.com, **Website:** jagadishwarpharma.com, **Tel.:** +91 9163513015

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023**

(Rupees In Lacs)

|              | Particulars                                                                                                         | Quarter Ended    |                  |                  | Nine Months Ended |                  | Year Ended       |
|--------------|---------------------------------------------------------------------------------------------------------------------|------------------|------------------|------------------|-------------------|------------------|------------------|
|              |                                                                                                                     | 31-12-2023       | 30-09-2023       | 31-12-2022       | 31-12-2023        | 31-12-2022       | 31-03-2023       |
|              |                                                                                                                     | (Unaudited)      | (Unaudited)      | (Unaudited)      | (Unaudited)       | (Unaudited)      | (Audited)        |
| <b>1</b>     | <b>Income From Operations</b>                                                                                       |                  |                  |                  |                   |                  |                  |
|              | (a) Net Sales / Income from Operations<br>(Net of Excise Duty)                                                      | -                | -                | -                | -                 | -                | -                |
|              | (b) Other Operating Income                                                                                          | 7.366            | 9.605            | 11.256           | 22.340            | 33.386           | 44.140           |
|              | <b>Total Income from Operations</b>                                                                                 | <b>7.366</b>     | <b>9.605</b>     | <b>11.256</b>    | <b>22.340</b>     | <b>33.386</b>    | <b>44.140</b>    |
| <b>2</b>     | <b>Expenses</b>                                                                                                     |                  |                  |                  |                   |                  |                  |
|              | (a) Cost of materials consumed                                                                                      | -                | -                | -                | -                 | -                | -                |
|              | (b) Purchase of stock-in-trade                                                                                      | -                | -                | -                | -                 | -                | 2.768            |
|              | (c) Changes in inventories of finished goods,<br>work-in-progress and stock-in-trade                                | -                | -                | -                | -                 | -                | (2.768)          |
|              | (d) Employee benefits expense                                                                                       | 10.802           | 7.274            | 5.547            | 23.557            | 19.615           | 25.106           |
|              | (e) Depreciation and amortisation expense                                                                           | -                | -                | -                | -                 | -                | -                |
|              | (f) Other expenses                                                                                                  | 1.580            | 2.695            | 2.073            | 8.947             | 8.505            | 10.495           |
|              | <b>Total Expenses</b>                                                                                               | <b>12.381</b>    | <b>9.969</b>     | <b>7.620</b>     | <b>32.504</b>     | <b>28.120</b>    | <b>35.601</b>    |
| <b>3</b>     | <b>Profit / (Loss) from Operations before other<br/>income, finance costs and exceptional items (1-2)</b>           | <b>(5.015)</b>   | <b>(0.364)</b>   | <b>3.636</b>     | <b>(10.164)</b>   | <b>5.267</b>     | <b>8.539</b>     |
| <b>4</b>     | Other Income                                                                                                        | -                | -                | -                | -                 | -                | -                |
| <b>5</b>     | <b>Profit / (Loss) from ordinary activities before<br/>finance costs and exceptional items (3-4)</b>                | <b>(5.015)</b>   | <b>(0.364)</b>   | <b>3.636</b>     | <b>(10.164)</b>   | <b>5.267</b>     | <b>8.539</b>     |
| <b>6</b>     | Finance Costs                                                                                                       | -                | -                | -                | -                 | -                | -                |
| <b>7</b>     | <b>Profit / (Loss) from ordinary activities after<br/>finance costs but before exceptional items (5-6)</b>          | <b>(5.015)</b>   | <b>(0.364)</b>   | <b>3.636</b>     | <b>(10.164)</b>   | <b>5.267</b>     | <b>8.539</b>     |
| <b>8</b>     | Exceptional Items                                                                                                   | -                | -                | -                | -                 | -                | -                |
| <b>9</b>     | <b>Profit / (Loss) from ordinary activities before tax<br/>(7-8)</b>                                                | <b>(5.015)</b>   | <b>(0.364)</b>   | <b>3.636</b>     | <b>(10.164)</b>   | <b>5.267</b>     | <b>8.539</b>     |
| <b>10</b>    | Tax Expense                                                                                                         | 0.728            | 0.734            | 1.112            | 2.225             | 3.325            | 2.220            |
| <b>11</b>    | <b>Net Profit / (Loss) from ordinary activities after<br/>tax (9-10)</b>                                            | <b>(5.743)</b>   | <b>(1.098)</b>   | <b>2.524</b>     | <b>(12.389)</b>   | <b>1.942</b>     | <b>6.319</b>     |
| <b>12</b>    | Extraordinary items (net of tax Rs. Nil Lakhs)                                                                      | -                | -                | -                | -                 | -                | -                |
| <b>13</b>    | <b>Net Profit / (Loss) for the period (11-12)</b>                                                                   | <b>(5.743)</b>   | <b>(1.098)</b>   | <b>2.524</b>     | <b>(12.389)</b>   | <b>1.942</b>     | <b>6.319</b>     |
| <b>14</b>    | Share of Profit / (loss) of associates                                                                              | -                | -                | -                | -                 | -                | -                |
| <b>15</b>    | Minority Interest                                                                                                   | -                | -                | -                | -                 | -                | -                |
| <b>16</b>    | <b>Net Profit / (Loss) after taxes, minority interest<br/>and share of profit / (loss) of associates (13-14-15)</b> | <b>(5.743)</b>   | <b>(1.098)</b>   | <b>2.524</b>     | <b>(12.389)</b>   | <b>1.942</b>     | <b>6.319</b>     |
| <b>17</b>    | <b>Paid-up Equity Share Capital<br/>(Face Value of Rs.10/- per Share)</b>                                           | <b>2,970.019</b> | <b>2,970.019</b> | <b>2,970.019</b> | <b>2,970.019</b>  | <b>2,970.019</b> | <b>2,970.019</b> |
| <b>18</b>    | Reserves (excluding Revaluation Reserve) as shown<br>in the Audited Balance Sheet of the previous year              | -                | -                | -                | -                 | -                | 129.085          |
| <b>19.i</b>  | <b>Earnings Per Share (before extraordinary items)<br/>(of Rs. 10/- each) (not annualised)</b>                      |                  |                  |                  |                   |                  |                  |
|              | (a) Basic                                                                                                           | -                | -                | 0.01             | -                 | 0.01             | 0.02             |
|              | (b) Diluted                                                                                                         | -                | -                | 0.01             | -                 | 0.01             | 0.02             |
| <b>19.ii</b> | <b>Earnings Per Share (after extraordinary items)<br/>(of Rs. 10/- each) (not annualised)</b>                       |                  |                  |                  |                   |                  |                  |
|              | (a) Basic                                                                                                           | -                | -                | 0.01             | -                 | 0.01             | 0.02             |
|              | (b) Diluted                                                                                                         | -                | -                | 0.01             | -                 | 0.01             | 0.02             |

**Notes:**

- 1 The above results have been reviewed by the audit committee and approved by the Board of Directors of the Company in its meeting held on 09/02/2024.
- 2 The standalone financial results of the Company for the quarter and nine months ended 31st December, 2023 have been unaudited by the Statutory Auditors.
- 3 Statutory Auditors have carried out a "Limited Review" of the above financial results for the quarter/nine months ended 31st December, 2023.
- 4 Previous Period / Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited



Swapan Sarkar  
Director  
(DIN: 05149442)

Place : Kolkata  
Date : 09/02/2024





Review report to Impala Jagadishwar Pharmaceutical Works Limited


We have reviewed the accompanying statement of unaudited financial results of Jagadishwar Pharmaceutical Works Limited (Name of the Company) for the period ended 31st December, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For **Rajesh U Shah & Associates**  
Chartered Accountants

  
**Rajesh Shah**

Proprietor

Membership Number: 056550

Firm Regn. No.: 327799E

UDIN: 24056550BJZZAK3284



Place: Kolkata

Date: February 9, 2024